NeoGenomics, Inc. (NEO) Short Interest Update

NeoGenomics, Inc. (NASDAQ:NEO) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 4,262,837 shares, an increase of 42.7% from the December 14th total of 2,987,331 shares. Currently, 4.9% of the company’s shares are short sold. Based on an average daily volume of 1,342,008 shares, the short-interest ratio is currently 3.2 days.

NEO opened at $15.23 on Wednesday. NeoGenomics has a one year low of $7.08 and a one year high of $19.04. The stock has a market capitalization of $1.44 billion, a PE ratio of 253.83 and a beta of 0.43. The company has a current ratio of 4.13, a quick ratio of 3.98 and a debt-to-equity ratio of 0.32.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, October 30th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $69.10 million for the quarter, compared to the consensus estimate of $66.13 million. NeoGenomics had a return on equity of 2.63% and a net margin of 1.70%. The firm’s quarterly revenue was up 16.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.01 EPS. On average, research analysts expect that NeoGenomics will post 0.11 earnings per share for the current year.

In related news, insider Robert J. Shovlin sold 216,493 shares of the stock in a transaction dated Monday, November 12th. The stock was sold at an average price of $17.00, for a total transaction of $3,680,381.00. Following the transaction, the insider now owns 339,884 shares of the company’s stock, valued at approximately $5,778,028. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Kevin C. Johnson sold 66,007 shares of the stock in a transaction dated Friday, November 9th. The stock was sold at an average price of $17.03, for a total value of $1,124,099.21. Following the transaction, the director now directly owns 97,873 shares in the company, valued at approximately $1,666,777.19. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,829,788 shares of company stock worth $213,793,738. Corporate insiders own 12.20% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in shares of NeoGenomics by 22.4% in the 3rd quarter. BlackRock Inc. now owns 5,079,026 shares of the medical research company’s stock valued at $77,960,000 after purchasing an additional 929,697 shares during the last quarter. Vanguard Group Inc grew its stake in shares of NeoGenomics by 24.0% in the 3rd quarter. Vanguard Group Inc now owns 3,839,641 shares of the medical research company’s stock valued at $58,939,000 after purchasing an additional 743,245 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of NeoGenomics by 24.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,839,641 shares of the medical research company’s stock valued at $58,939,000 after purchasing an additional 743,245 shares during the last quarter. Eagle Asset Management Inc. purchased a new position in shares of NeoGenomics in the 3rd quarter valued at approximately $33,116,000. Finally, Carillon Tower Advisers Inc. acquired a new stake in shares of NeoGenomics in the 3rd quarter valued at approximately $30,740,000. Hedge funds and other institutional investors own 83.19% of the company’s stock.

A number of research firms have issued reports on NEO. BidaskClub raised NeoGenomics from a “sell” rating to a “hold” rating in a research report on Thursday, January 10th. ValuEngine raised NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 10th. Zacks Investment Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating and set a $21.00 price target on the stock in a research report on Saturday, November 3rd. Raymond James reaffirmed a “buy” rating and issued a $24.00 price target on shares of NeoGenomics in a research report on Tuesday, December 4th. Finally, First Analysis set a $16.00 price target on NeoGenomics and gave the company a “buy” rating in a research report on Tuesday, September 18th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $19.33.

WARNING: This article was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.chaffeybreeze.com/2019/01/16/neogenomics-inc-neo-short-interest-update.html.

NeoGenomics Company Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Featured Article: Yield Curve

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply